Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables

Sastre, Javier; Maestro, M.L.; Puente, Javier; Veganzones, Silvia; Alfonso, Rosario; Rafael, Sara; García-Sáenz, José Ángel; Vidaurreta, Marta; Martín, Miguel; Arroyo, Manuel; Casla, María Teresa Sanz; Dı́az-Rubio, Eduardo

doi:10.1093/annonc/mdm583

Cited by 202 publications

(154 citation statements)

References 13 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…18). This discrepancy can be explained by the fact that Sastre et al performed blood collection after operation in TNM stage I to III colorectal cancer patients that most of them had partial or complete clearance of CTCs (18). In fact, the percentage of CK20 pCTC detection in our cohort of colorectal cancer patients at their first follow-up after operation was only 28.7% (29 of 101).…”

Section: Discussionmentioning

confidence: 66%

“…Previous studies indicated that immunomagnetic enrichment CTC detection using broad-spectrum antibody is very promising only in metastatic breast cancer (5 -7), whereas there are still very scanty reports in colorectal cancer (18,22,23). Using this refined immunomagnetic enrichment assay with standardized immunocytochemical staining and stringent assessment criteria, no CK20 pCTC was found in all blood samples from patients with breast cancer, prostate cancer, liver cancer, and lung cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Wong

Chan

Yue

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Current immunomagnetic enrichment method can only detect general epithelial antigens of circulating tumor cells (CTC). Further characterization of the CTCs to provide specific information on the tumor type is not possible.We attempted to overcome this drawback by developing the methodology for using a gastrointestinal-specific anti-cytokeratin (CK) 20 antibody to detect CTCs in colorectal cancer patients' blood. Experimental Design: The protocol was validated using a colorectal cancer SW480 cell line. The clinical significance of findings in colorectal cancer was investigated by detecting CK20-positive CTCs (pCTC) in patients with colorectal cancer, other common cancers, colorectal adenoma, benign colorectal diseases, and normal subjects. Moreover, the malignant nature of CK20 pCTCs was examined by comparing chromosome 17 aberration patterns with those from the corresponding primary tumors. Results: The assay successfully showed CK20-positive SW480 cells. When applied in patient samples, the detection rates were 62% (132 colorectal cancer patients; median number = 11 CTCs), 0% (120 patients with other common cancers), 6% (50 colorectal adenoma patients), 0% (120 patients with benign colorectal diseases), and 0% (40 normal subjects). Furthermore, statistical analysis showed that CK20 pCTC numbers were associated with tumor-node-metastasis stage and lymph node status. Using the median CK20 pCTC numbers as the cutoff points, stratified groups of colorectal cancer patients had significant differences in their recurrence, metastasis, and survival. Finally, chromosome 17 aneusomy in 90% of colorectal cancer patients with CK20 pCTCs matched with those from the primary tumors. Conclusions: Detection of CK20 pCTCs using the new protocol could generate clinically important information for colorectal cancer patients.

show abstract

Section: Discussionmentioning

confidence: 66%

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Wong

Chan

Yue

et al. 2009

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…These circulating tumor cells can be detected in the blood of patients with colo-rectal cancer (CRC) before the development of metastasis (Glaves, 1983). Circulating tumor cells (CTCs) have been detected in the peripheral blood of patients with a variety of metastatic solid tumors at varying concentrations using a variety of methods, such as RT-PCR, immunocytochemistry, immunoflorescence and flow cytometry (Jonas et al, 1996: Nagrath et al, 2007: Sastre et al, 2008: Marrinucci et al, 2010. The majority of these cells will die, it has been estimated that fewer than 0.01% of CTCs will implant and form metastasis (Fidler, 1973), and most CTCs are cleared from the circulation within 24 hours (Fidler, 1970).…”

Section: Introductionmentioning

confidence: 99%

Cytomorphology of Circulating Tumor Cells and Cell Clusters in Chilean Patients with Colo-Rectal Cancer

Murray

Albarran

et al. 2012

Int. J. Morphol.

View full text Add to dashboard Cite

SUMMARY:The aim of this study was to determine the cytomorphological characteristics of circulating tumor cells (CTCS) in patients with colo-rectal cancer and compare them with the primary tumor and metastasis. CTCS were obtained from blood using differential gel centrifugation and detected using standard immunocytochemistry using anti-CEA. Primary CTCs were defined as those detected before surgery and secondary CTCs those detected after. Surgical specimens of the primary tumor and metastasis were evaluated using standard histological methods with hematoxillin and eosin. CTCs both primary and secondary retained the cytomorphological characteristics of the primary tumor, showing marked intra-patient pleomorphism. There were no differences between primary and secondary CTCs in their cytomorphological features. CTCs from patients with signet ring tumors showed the presence of intracellular mucin deposits. Groups of 3 or more CTCs were only seen in patients with metastasis, whereas duplets of CTcs were seen in patients with metastatic and non-metastatic colo-rectal cancer. This study provides an initial analysis of the cytomorphological features of CTCs, providing a foundation for further investigation into the significance and metastatic potential of CTCs.

show abstract

“…Progress in the detection of CTC was achieved by immunohistochemistry testing [6] and, more recently, by highly sensitive PCR techniques [7][8][9]. In patients with colorectal cancer, the presence of CTC in peripheral blood was repeatedly confirmed and their detection ranged from 20% for localized disease and 60% in advanced CRC [10][11][12][13][14][15][16][17][18]. The clinical relevance of CTC as an independent prognostic factor was documented for cases in patients with positive CTC at diagnosis who had poorer prognosis than patients with negative CTC [10,[12][13][14][16][17][18][19][20][21][22][23][24].…”

mentioning

confidence: 99%

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery

et al. 2016

View full text Add to dashboard Cite

Background. The presence of circulating tumor cells (CTC) has been reported in patients with advanced colorectal cancer. Monitoring CTC (also known as a liquid-biopsy) has recently become the center of interest for low-invasive monitoring of cancer progression and predictive biomarkers testing. Along with high-cost technology and a complex methodology, a straightforward method based on magnetic beads enrichment followed by RT-PCR is set to allow for routine CTC analysis in colorectal cancer patients. Objectives. The main purpose of this study was to evaluate the possibility of CTC detection in routine monitoring of patients starting before and continuing after surgery. Material and Methods. The investigated group consisted of 30 patients mainly in advanced stages of colorectal cancer. In all patients, CTC detection was performed prior to surgery, in a subset of 14 patients additional sampling was done during and after surgery. In all cases, peripheral blood was processed using AdnaTest ColonCancer kit, which relies on enriching CTCs using EpCAM-functionalized magnetic beads and subsequently identifying tumorspecific CEA, EGFR and GA733-2 mRNA transcripts. Results. Out of all the tested samples, CTC were found in one patient suffering from advanced disease with lung and liver metastases. There, however, the positive finding was confirmed in 3 consecutive samples acquired before, during and shortly after palliative R2 resection. Conclusions. The presence of CTC may be used to observe post-operative disease development. Due to the overall low CTC detection, further technology development may be necessary before its universal applicability to manage colorectal cancer patients (Adv Clin Exp Med 2016, 25, 6, 1273-1279).

show abstract

Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables

Abstract: CTCs detection by CellSearch is a highly reproducible method that correlates with stage but not with other clinical and morphological variables in patients with colorectal cancer. Colon cancer tumor cells are detectable in all stages. Further studies are warranted.

Cited by 202 publications

References 13 publications

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Clinical Significance of Cytokeratin 20-Positive Circulating Tumor Cells Detected by a Refined Immunomagnetic Enrichment Assay in Colorectal Cancer Patients

Cytomorphology of Circulating Tumor Cells and Cell Clusters in Chilean Patients with Colo-Rectal Cancer

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery

Contact Info

Product

Resources

About